The president of The University of Texas, M. D. Anderson Cancer Center, John Mendelsohn, has been chosen as a co-recipient of a 2006 Dan David Prize . This announcement was made in Paris, for his path breaking research in Cancer Therapy.
The Dan David Foundation which is located at the Tel Aviv University distributed these annual awards which consist of three prizes of $1 million each to laureates chosen in areas where the contribution is immense and path breaking.
"It is a tremendous honor to be awarded the Dan David Prize," Mendelsohn says. "It's especially gratifying to be honored for research that has played a role in the future care of patients with cancer. I am pleased to share this award with Dr. Schlessinger whom I have known for many years as a pioneer in the field of growth factor signaling. We have published one research article together."
This 2006, "Future Dimension Award" focuses on Cancer Therapy and according to the foundation, Mendelson was awarded the prize for "pioneering the rapidly developing field of antibody-mediated cancer therapy in general and that of antibodies to growth factors in particular". Nearly two decades have seen Mendelson steeped in research on how growth factors impact the multiplication of cancer cells.
Mendelssohn's strengths are clinical and laboratory research and has also steered M. D. Anderson in its administration, over the last ten years. M. D. Anderson has to its credit, the acclaim of being named the top cancer hospital in the nation four years in succession in the last five years, as per the "America's Best Hospitals" survey.